Answers are grounded in this paper and cite their sources.
: PCSK9 monoclonal antibodies when added to background statin therapy, lowers LDL-C to previously unattainable levels. This is safe with little undesirable effects and impacts positively on cardiovascular disease. Current guidance limits their use to primary prevention. Cost effectiveness should be taken into consideration before allowing a wider use of this new class of cholesterol lowering therapy and more data on their long-term safety is welcome.
No takes yet. Share an insight, caveat, or question.
Iqbal et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: